Business Context and Reporting Period
This Form 8-K was filed by Oncocyte Corporation (trading symbol: OCX) on January 8, 2025, reporting events occurring on January 2, 2025. The filing details a material definitive agreement regarding the company's office lease at 15 Cushing Irvine, California.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed relates to a lease security instrument:
- Letter of Credit Amount: $1,700,000 (current balance securing the lease).
- Restricted Cash: Corresponds to the Letter of Credit Amount on the balance sheet.
Material Changes
The primary change involves an amendment to the Original Lease Agreement (dated December 23, 2019) with landlord Cushing Ventures, LLC and subtenant Induce Biologics USA, Inc. Key changes include:
- Lease Termination and Replacement: All rights to extend the Original Lease were terminated. The Original Lease will expire on October 31, 2027. It has been superseded by a Replacement Lease between Induce and Cushing.
- Letter of Credit Reduction: Commencing July 1, 2025, the $1,700,000 Letter of Credit will be reduced by $60,714.29 on the first day of each calendar month until fully reduced, provided the Company is not in default.
- Cash Impact: Reductions in the Letter of Credit will correspondingly reduce the Company's Restricted Cash balance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of general business risks. The only contingency noted is that the reduction of the Letter of Credit is conditional upon the Company not being in default under the Original Lease terms. The filing explicitly states there can be no assurance that the Letter of Credit Amount will be reduced.
Investor Verification Checklist
- Verify the current status of the Company's Restricted Cash on the most recent balance sheet to confirm the $1,700,000 figure.
- Review the full text of the Amendment (Exhibit 10.1) for any covenants or default conditions that could prevent the scheduled reduction of the Letter of Credit.
- Confirm the operational impact of the lease transfer to Induce Biologics USA, Inc. and the Company's future occupancy arrangements post-October 31, 2027.